Scientific exchange · Dr. Liam Quinn

15 Jun 2026 · Phone · Dr. Liam Quinn, Royal Marsden · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0072—

Capture insight from this engagement

Location: Vall d'Hebron
Therapeutic area: Oncology
Country: United Kingdom
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Sequencing after progression
Chemotherapy-free first line
Brain-metastasis subgroup data

Scientific content used

VOYAGE-1 pivotal data summary
VTX core scientific deck v3.2

Questions raised

What is the evidence for re-challenge with checkpoint inhibitors after progression on vantrelimab?

Notes

Scientific exchange with radiation oncologist at Vall d'Hebron. Discussed sequencing after progression, chemotherapy-free first line, brain-metastasis subgroup data.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 4
Depth of exchange: 1
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0072

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
01 Sept 2026, 18:38 UTC	Close	RARachel Adeyemi	progress	— → Reviewed	—	API